摘要:
A method of treating or preventing post-operative ileus in a mammalian subject is disclosed. The method involves administering to the subject, a pharmaceutically effective amount of a compound that is effective in (i) preventing mast cell degranulation, (ii) inhibiting tryptase and chymase, and (iii) antagonizing PAR-2. The treatment is based on the discoveries that proteinase-activated receptor 2 is expressed in colonic muscle cells, and that activation of PAR-2 inhibits colonic motility. The PAR-2 receptor is activated, at least in part, by tryptase and chymase, produced by infiltration and degranulation of mast cells.
摘要:
An improved immunogenic composition against human gastrin 17 comprising the peptide pGlu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Ser-Ser-Pro-Pro-Pro-Pro-Cys (SEQ ID NO.: 1) coupled to an immunogenic carrier and pharmaceutical compositions containing the same.
摘要翻译:包含肽pGlu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Ser-Ser-Pro-Pro-Pro-Pro-Pro-Cys(SEQ ID NO:1)的针对人胃泌素17的改进的免疫原性组合物, 偶联至免疫原性载体和含有它的药物组合物。
摘要:
Three new monoclonal antibodies, MU78, MT334, and MQ49, and the hybridoma cell lines producing these, are disclosed. The antibodies specifically bind to mucin-like antigens with distribution over various carcinomas.
摘要:
The protein PP.sub.4 which has(a) an electrophoretic mobility in the range between that of .alpha..sub.1 and .alpha..sub.2 globulins;(b) an isoelectric point of 4.85.+-.0.15;(c) a sedimentation coefficient s.sub.20,w.sup.0 of 3.3.+-.0.2S;(d) a molecular weight determined in polyacrylamide gel containing sodium dodecylsulfate (DSD) of 35,000.+-.5,000;(e) an extinction coefficient E.sub.1 cm.sup.1% (280 nm) of 5.9.+-.0.6;(f) a carbohydrate content of 2.4.+-.0.94% (g/100 g) (mannose 0.3.+-.0.2%, galactose 0.4.+-.0.2%, xylose 0.1.+-.0.4%, glucose 0.2.+-.0.1%, glucosamine 1.0.+-.0.2% and neuraminic acid 0.4.+-.0.2%) and(g) a specified aminoacid composition, and a process for its preparation are described. PP.sub.4 can be used to prepare antisera which can be employed to detect and determine PP.sub.4 in body fluids in order to diagnose diseases of particular organs, as a "marker" to monitor the progress of a disease or to check therapy.
摘要:
A process for obtaining salts of amino-acids with polysulfuric esters of glycopeptides comprises reacting an aqueous solution of a sulfoglycopeptide in the acid form with a slight excess of one or more free amino-acids, dialysing the solution of the obtained salt and finally separating the product by dilution and precipitation with selective solvents or by concentration under reduced pressure followed by a lyophilization process. The thus obtained salts of natural or synthetic amino-acids with sulfoglycopeptides possess a remarkable anti-inflammatory pharmacological action useful for treating gastro-duodenal ulcerous phenomena without dangerous side effects.
摘要:
IMPROVED PROTEIN FEED MATERIAL FOR RUMINANTS WHICH IS RESISTANT TO DIGESTIVE BREAKDOWN IN THE RUMEN BUT NOT IN THE ABOSMASUM AND/OR INTESTINES WHICH COMPRISES THE REACTION PRODUCT OF A PROTEIN-CONTAINING FEED MATERIAL AND AN ALKYL OR ARYL SULFONYL HALIDE. EXEMPLARY OF SUCH SULFONYL HALIDES IS P-TOLYL SULFONYL CHLORIDE.
摘要:
Glycopeptides are extracted from the gastric mucosa or duodenum of swine by hydrolysis of the animal organ under specified conditions, followed by separation of acidic hydrolysis byproducts and dilution of the extraction product with a nonsolvent to precipitate the glycopeptides.
摘要:
A PROCESS FOR PURIFYING INTRINSIC FACTOR BY A BATCH CHROMATOGRAPHY PROCESS WHICH UTILIZES AN ION EXCHANGE RESIN; AND THE RESULTANT HIGH PURITY INTRINSIC FACTOR. TYPICALLY, IMPURE INTRINSIC FACTOR IS DISSOLVED IN A BUFFER SOLUTION HAVING RELATIVELY LOW PH AND IONIC STRENGTH, AND THE RESULTANT SOLUTION IS CONTACTED WITH A CELLULOSIC EXCHANGE RESIN. THE RESIN IS SEPARATED FROM THE SOLUTION AND THE PURIFIED INTRINSIC FACTOR IS ELUTED THEREFROM WITH A BUFFER SOLUTION HAVING A HIGHER PH AND IONIC STRENGTH THAN THE BUFFER SOLUTION IN WHICH THE IMPURE INTRINSIC FACTOR WAS DISSOLVED. THE PRODUCT IS RECOVERED FROM THE ELUATE BY EVAPORATING THE LIQUID SOLVENT. THE RESIDUE, WHICH IS THE PURIFIED PRODUCT, HAS A POTENCY OF AT LEAST 1 N.F. UNIT IN AMOUNTS AS LOW AS 0.5 MG.